Target type: biologicalprocess
A behavioral interaction between organisms in which one organism has the intention of inflicting physical damage on another individual. [GOC:hjd]
Aggressive behavior is a complex and multifaceted biological process that involves a interplay of genetic, neurological, hormonal, and environmental factors. It is characterized by a range of behaviors aimed at inflicting harm or dominance over others, often involving physical aggression, verbal threats, or intimidation.
At the neurological level, several brain regions are implicated in aggressive behavior. The amygdala, a structure involved in processing emotions, plays a crucial role in fear and aggression. The hypothalamus, responsible for regulating hormones and basic drives, is also involved in aggression, particularly in response to threats. The prefrontal cortex, responsible for executive functions such as planning and impulse control, plays a role in inhibiting aggressive behavior.
Neurotransmitters, such as serotonin, dopamine, and norepinephrine, are also involved in regulating aggression. Serotonin is often associated with inhibiting aggression, while dopamine and norepinephrine are linked to its promotion. However, the exact role of these neurotransmitters in aggression is complex and can vary depending on the context.
Hormones, particularly testosterone, have been linked to aggressive behavior. Studies have shown that higher levels of testosterone are often associated with increased aggression in both animals and humans. However, the relationship between testosterone and aggression is not straightforward, and other factors, such as social context, can influence this link.
Environmental factors, such as childhood experiences, social learning, and cultural norms, can also significantly influence aggressive behavior. Individuals who experience abuse or neglect during childhood are more likely to engage in aggressive behavior later in life. Social learning theories suggest that aggression can be learned through observation and imitation. Cultural norms and values can also shape how aggressive behavior is expressed and perceived.
It is important to note that aggressive behavior is not a monolithic concept. There are different types of aggression, such as reactive aggression, proactive aggression, and instrumental aggression, each with its own underlying mechanisms. Additionally, the expression of aggression can vary widely across individuals and situations.
Understanding the biological underpinnings of aggressive behavior is crucial for developing effective interventions to prevent and manage aggression. Research in this area continues to shed light on the complex interplay of factors that contribute to this complex behavior.'
"
Protein | Definition | Taxonomy |
---|---|---|
Nuclear receptor subfamily 2 group E member 1 | A nuclear receptor subfamily 2 group E member 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y466] | Homo sapiens (human) |
Substance-P receptor | A substance-P receptor that is encoded in the genome of human. [PRO:WCB, UniProtKB:P25103] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
astemizole | astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects. | benzimidazoles; piperidines | anti-allergic agent; anticoronaviral agent; H1-receptor antagonist |
clotrimazole | conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes | antiinfective agent; environmental contaminant; xenobiotic | |
econazole | 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 4-chlorobenzyl group. econazole : A racemate composed of equimolar amounts of (R)- and (S)-econazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. Econazole: An imidazole derivative that is commonly used as a topical antifungal agent. | dichlorobenzene; ether; imidazoles; monochlorobenzenes | |
miconazole | 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes. Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion. | dichlorobenzene; ether; imidazoles | |
propafenone | propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. | aromatic ketone; secondary alcohol; secondary amino compound | anti-arrhythmia drug |
propranolol | propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3. Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs. | naphthalenes; propanolamine; secondary amine | anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic |
dexpropranolol | propranolol | ||
substance p | peptide | neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent | |
paroxetine | paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression. | aromatic ether; benzodioxoles; organofluorine compound; piperidines | antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor |
phenylalanylphenylalanylamide | |||
cp 96345 | CP 96345: structure given in first source; potent nonpeptide antagonist of the substance P (NK1) receptor; CP 96344 is enantiomer of CP 96345 | ||
sr 48968 | SR 48968: structure given in first source; neurokinin A antagonist; tachykinin receptor antagonist; SR 48965 is the inactive R-enantiomer of SR 48968 | ||
7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one | 7,7-diphenyl-2-(1-imino-2-(2-methoxyphenyl)ethyl)perhydroisoindol-4-one: structure given in first source; RP 68651 is the inactive (3aS,7aS)-isomer; substance P antagonist | ||
tryptoline | tryptoline: neurotoxic factor that may be involved in development of Parkinson's disease; enzymatic prep from human brain converts tryptamine to tryptoline; RN given refers to parent cpd; structure | beta-carbolines | |
senktide | |||
tadalafil | benzodioxoles; pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent | |
(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine | (2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine: structure given in first source | ||
l 703606 | L 703606: structure given in first source | ||
3,5-bis(trifluoromethyl)benzyl n-acetyltryptophan | 3,5-bis(trifluoromethyl)benzyl N-acetyltryptophan: structure given in first source; substance P and neurokinin receptor antagonist | ||
l 733060 | 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine: RN given refers to (2S-cis)-isomer; L-733,061 is pharmacologically inactive; structure in first source | piperidines | |
win 64821 | WIN 64821: a dimerized Trp-Phe condensate; structurally similar to verticillins and chaetocins; a nonpeptide neurokinin antagonist; structure given in first source; substance P antagonist | ||
n-desisopropylpropranolol | N-desisopropylpropranolol: RN given refers to parent cpd | ||
substance p, pro(9)- | substance P, Pro(9)-: RN given refers to the (L-Pro)-isomer; RN for cpd without isomeric designation not available 3/91 | ||
substance p, sar(9)-met(o2)(11)- | substance P, Sar(9)-Met(O2)(11)-: a neurokinin-1 receptor agonist | ||
ranatachykinin a | ranatachykinin A: a tachykinin in frog (Rana catesbeiana) brain and intestine | ||
sr 142806 | |||
tamoxifen | stilbenoid; tertiary amino compound | angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator | |
cp 99994 | 3-(2-methoxybenzylamino)-2-phenylpiperidine: selective NK(1) receptor antagonist; CP-100263 is the inactive enantiomer | ||
neurokinin a | Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI. | ||
neurokinin b | Neurokinin B: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ A with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the URINARY BLADDER and UTERUS. | polypeptide | |
sb 223412 | SB 223412: SB-223412 is the (S)-(-)-isomer; RN given for (S)-isomer; structure in first source | ||
seglitide | seglitide: more potent than somatostatin for inhibition of insulin, glucagon & growth hormone release; used experimentally in treatment of Alzheimer's disease; somatostatin receptor antagonist | ||
biphalin | biphalin: enkephalin dimer; two fragments of Ala(2)-enkephalin are connected by a diamine bridge to form above cpd; structure given in first source | ||
netupitant | netupitant : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoic acid with the secondary amino group of N-methyl-4-(2-methylphenyl)-6-(4-methylpiperazin-1-yl)pyridin-3-amine; an antiemetic used in combination with palonosetron hydrochloride (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy. netupitant: orally active neurokinin-1 receptor antagonist | aminopyridine; monocarboxylic acid amide; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; toluenes | antiemetic; neurokinin-1 receptor antagonist |
sb 222200 | quinolines | ||
sb 218795 | SB 218795: structure in first source | quinolines | |
substance p (6-11), tyr(6)-d-phe(7)-d-his(9)- | substance P (6-11), Tyr(6)-D-Phe(7)-D-His(9)-: substance P antagonist | ||
vofopitant | |||
pd 154075 | PD 154075: a non-peptide tachykinin NK1 receptor antagonist; structure given in first source | ||
edotecarin | |||
(2s,3s)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine | (2S,3S)-2-phenyl-3-((5-trifluoromethoxy-2-methoxy)benzylamino)piperidine: structure given in first source | ||
vestipitant | |||
ly 306740 | LY 306740: LY-307679 is the inactive enantiomer | ||
sdz nkt 343 | SDZ NKT 343: structure in first source | ||
orvepitant | |||
zd 6021 | ZD 6021: structure in first source | ||
tak 637 | TAK 637: structure in first source | ||
casopitant | piperidines | ||
nkp 608 | |||
dnk 333 | DNK 333: a dual neurokinin NK1/NK2 receptor antagonist; structure in first source | ||
4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | |||
rolapitant | azaspiro compound; ether; organofluorine compound; piperidines; pyrrolidin-2-ones | antiemetic; neurokinin-1 receptor antagonist | |
spiroquinazoline | spiroquinazoline: isolated from the fungus Aspergillus flavipes; structure given in first source; substance P antagonist | ||
ditryptophenaline | ditryptophenaline: structure in first source | ||
serlopitant | |||
nitd 609 | NITD 609: an antimalarial and coccidiostat; structure in first source | ||
aprepitant | aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING. | (trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles | antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist |
l 742694 | L 742694: a neurokinin-1 receptor antagonist; structure given in first source |